NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters Agreement Related to Recently Acquired PreEMT™ Platform

May 3, 2018 11:24:56

Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) today announced that it has signed an agreement with an international biopharmaceutical company to assess the potential of PBIO’s recently acquired PreEMT™ platform to develop a unique manufacturing process and improve the quality of a key protein-based drug that’s currently under development. “We believe this contract will take three to four months to complete. Moreover, we have recently been contacted by several additional biopharmaceutical companies interested in evaluating our PreEMT disaggregation and refolding service in the development and manufacture of protein-based therapeutics,” Richard T. Schumacher, president and CEO of PBIO, stated in the news release. “Because of this early interest in the PreEMT platform, and because the BaroFold pressure-based technologies work on and will help sell our existing Barocycler instrumentation, we believe the BaroFold asset purchase will pay for itself very quickly. Finally, and importantly, should the PreEMT technology result in more efficient production of high quality protein-based therapeutics for any biopharmaceutical company developing new protein-based therapeutics, manufacturing-scale licenses have the potential to generate millions of dollars in annual royalty revenue.”

To view the full press release, visit

About Pressure BioSciences Inc.

Pressure BioSciences Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. For more information, visit the company’s website at

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office